Last Tuesday, a researcher in Chicago presented data so unexpected that oncologists in the audience actually gasped. The in vivo CAR-T results showed response rates nobody thought possible this early. While they were gasping, I was thinking about you - the B.Pharm graduate in Pune scrolling LinkedIn, wondering if oncology research has room for freshers. It does, and what happened at ASCO 2026 just expanded that room significantly.
I remember attending my first ASCO virtually back in 2015, feeling completely overwhelmed by the scientific jargon and unable to connect the dots between "breakthrough data" and "actual job opportunities." That disconnect is exactly what I want to help you bridge today. Let me walk you through what actually happened in Chicago this year, and more importantly, what it means for your career.
ASCO 2026's Biggest Announcements: What Actually Happened in Chicago
The oncology community left Chicago buzzing about three major storylines. Let me break each one down in plain terms.
The In Vivo CAR-T Data That Had Everyone Talking
The biggest scientific splash came from in vivo CAR-T therapy data. Now, if you have heard of CAR-T before, you probably know it as a treatment where doctors extract a patient's T cells, engineer them in a lab to recognize cancer, and then infuse them back. That is called ex vivo CAR-T, and it is complicated, expensive, and requires specialized manufacturing facilities.
What researchers presented at ASCO 2026 was something different: in vivo CAR-T, where the genetic engineering happens inside the patient's body. You inject a vector (think of it as a delivery vehicle) that reprograms the T cells while they are still in the bloodstream. The data presented was described as "nutty" by industry reporters, meaning the efficacy numbers were unexpectedly strong for such an early-stage approach.
Why does this matter beyond the science? Because in vivo CAR-T could dramatically simplify the manufacturing and logistics of cell therapy. Right now, CAR-T manufacturing is so complex that most of it happens in a handful of specialized facilities in the United States and Europe. If in vivo approaches work, suddenly you do not need those facilities. You need injection sites and monitoring capabilities, both of which India has in abundance.
Pfizer's Monthly Obesity Drug: Berobenatide Steps Into the Spotlight
The second major story was Pfizer's presentation of detailed Phase 2 data for berobenatide, an obesity drug they acquired from biotech company Metsera. The data showed that this drug could potentially be dosed monthly, which is a significant step up from the weekly injections required by current GLP-1 drugs like Wegovy and Zepbound.
Now, you might be thinking: "This is an obesity drug. What does it have to do with oncology careers?" Here is the connection that most freshers miss. Pfizer is an oncology giant. When Pfizer invests heavily in a new therapeutic area like obesity, they do not abandon their existing clinical trial infrastructure. They expand it. They hire more clinical research associates, more data managers, more pharmacovigilance specialists. And they do this globally, including in India.
Pfizer has a substantial presence in India through their clinical operations in Mumbai and Hyderabad. When their pipeline grows, their hiring grows. The berobenatide data suggests Pfizer will be running large-scale Phase 3 trials soon, and those trials will need sites in India.
A Historic First for Chinese Biotech
The third storyline that industry watchers noted was a historic first for a Chinese biotech asset at ASCO. While I cannot name the specific company without more details, what matters is the trend: Chinese biotechs are increasingly getting their drugs validated at major Western conferences. This matters for Indian freshers because many Chinese biotechs partner with Indian CROs for clinical trial execution. As these companies mature and their pipelines advance, they need trial sites and clinical research talent in India.
Which Companies Presented and Who Is Hiring in India
Let me give you the practical information you actually need. The major pharma companies that presented data at ASCO 2026 included AbbVie, Pfizer, Roche, and several mid-sized biotechs. Here is what their India hiring situations look like:
AbbVie has clinical operations in Bangalore and Mumbai. They recently received NHS England clearance for Elahere, their ovarian cancer drug, which signals continued investment in their oncology portfolio. AbbVie tends to hire experienced professionals, but they do take freshers into their drug safety and regulatory affairs teams.
Pfizer, as I mentioned, has substantial India operations. They actively recruit from campuses and hire freshers for clinical data management and pharmacovigilance roles. Starting salaries for freshers at Pfizer India typically range from Rs 4.5 to 6 lakhs per annum, depending on the role and location.
Roche has a major presence in Hyderabad through their Global Pharma Operations center. They hire freshers for clinical operations support roles, though competition is fierce. Roche also made headlines recently regarding policy disputes with the US government, but their India operations remain stable and growing.
The CROs that support these companies are where most freshers actually land their first jobs. IQVIA, Parexel, ICON, Syneos Health, and Covance all have significant India operations and actively hire freshers. If you are serious about getting into oncology clinical research, these CROs are your most realistic entry point.
Related reading on ClinPath:
- Decentralised Clinical Trials (DCT) in India: Complete Career Guide 2025 for Pharma Freshers
- Clinical Data Management Career in India 2025: Complete Guide for Freshers
- FDA Tobacco Warning 2025: What Indian Pharma Freshers Need to Know About Regulatory Intelligence
In Vivo CAR-T Data: What It Means for Clinical Research Jobs in India
Let me explain in vivo CAR-T in terms that will help you understand both the science and the career implications.
Photo by SiljeAO - on Pexels
Photo by SiljeAO - on Pexels
Understanding the Difference: Ex Vivo vs In Vivo CAR-T
Traditional CAR-T therapy (ex vivo) works like this: A patient goes to a hospital, and medical staff collect their blood through a process called leukapheresis. The blood is shipped to a specialized manufacturing facility, often in the United States or Europe. At that facility, technicians isolate the T cells and use viral vectors to insert a gene that makes the T cells recognize a specific protein on cancer cells. This process takes two to four weeks. Then the engineered cells are shipped back to the hospital, and the patient receives them through an infusion.
The logistics are nightmarish. You are shipping living cells across continents. Temperature control is critical. Timing is critical. And the cost runs into lakhs of dollars per patient.
In vivo CAR-T skips most of this complexity. Instead of extracting cells, engineering them, and putting them back, you inject the patient with a vector that does the engineering inside their body. The T cells get reprogrammed while they are still in the bloodstream.
The ASCO 2026 data showed that this approach can actually work in humans, not just in mice. The response rates were strong enough that multiple companies are now racing to develop their own in vivo platforms.
Why This Matters for CROs and Clinical Research in India
Here is where it gets interesting for your career. Traditional ex vivo CAR-T trials are almost impossible to run in India because of the manufacturing requirements. There are very few facilities in India capable of producing CAR-T cells to the standards required by the FDA or EMA. This has meant that India has largely been left out of the CAR-T clinical trial boom.
In vivo CAR-T changes this equation. If you do not need specialized manufacturing facilities, suddenly any hospital with an oncology department and a good clinical research team can potentially participate in trials. India has plenty of those.
The FDA recently issued draft guidance specifically aimed at accelerating cell and gene therapies. This guidance makes it easier for companies to leverage existing data and streamlines the development pathway. When you combine easier regulatory pathways with simpler manufacturing requirements, you get more trials. More trials mean more jobs.